PTH in the pathogenesis and treatment of glucocorticoid-lnduced osteoporosis

Frontiers of Hormone Research

Volumn 30, Issue , 2002, Pages 184-197

  Gennari, C ^a   Gonnelli, S ^a   Bruni, D ^a   Gennari, L ^b   Brandi, M L ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PARATHYROID HORMONE;

CHEMICALLY INDUCED DISORDER; HUMAN; OSTEOPOROSIS; PHYSIOLOGY; REVIEW;

GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE;

EID: 0036371806     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (58)

1. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990;112:352-364.
2. Reid IR: Glucocorticoid-induced osteoporosis: Assessment and treatment. J Clin Densitom 1998; 1:65-73.
3. Cushing H: Basophile adenomas. J Nerv Ment Dis 1932;76:50.
4. Manolagas SC, Weinstein RS: New developments in the pathogenesis and treatment of steroidinduced osteoporosis. J Bone Miner Res 1999;14:1061-1066.
5. Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV: Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int 1984;36:245-252.
6. Allen DB: Limitations of short-term studies in predicting long-term adverse effect of inhaled corticosteroids. Allergy 1999;54:29-34.
7. Lukert BP: Glucocorticoid and drug-induced osteoporosis; in Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 3. New York, LippincottRaven, 1999, pp 292-296.
8. Dempster DW: Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989;4:137-141.
9. Peck WA: Effects of glucocorticoids on bone cell metabolism and function. Adv Exp Med Biol 1984;171:111-119.
10. Reid R, Gray AB: Corticosteroid osteoporosis; in Reid DM (ed): Bailliere's Clinical Rheumatology. Osteoporosis. London, Bailliere-Tindall, 1993, pp 573-588.
11. Bonucci E, Dearden LC, Mosier HD Jr: Effects of glucocorticoid treatment on ultrastructure of cartilage and bone. Adv Exp Med Biol 1984;171:269-278.
12. Morrison N, Eisman J: Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res 1993;8:969-975.
13. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteoclasts by glucocorticoids: Potential mechanism of their deleterious effects on bone. J Cin Invest 1998;102:274-282.
14. BellidoT, Han L, Mocharla H, Said S, O'Brien C, Jilka RL, Manolagas SC: Overexpression of Bcl-2 renders osteoblastic cells refractory to glucocorticoid-induced apoptosis (abstract). Bone 1998;23:S324.
15. Reichardt HM, Kaestner KH, Tuckerman J, Kretz O, Wesseley O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G: DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-541.
16. Canalis E: Inhibitory actions of glucocorticoids on skeleton growth: Is local insulin-like growth factor I to blame? Endocrinology 1998;139:3041-3042.
17. Gennari C, Nuti R: Complications of corticosteroid therapy; in Christiansen C, Krane SM (eds): Advances in Corticosteroids. Langhorne/Pa, Adis International, 1993, pp 39-51.
18. Caniggia A, Nuti R, Lorè F, Vattimo A: Pathophysiology of adverse effects of glucoactive corticosteroids on calcium metabolism in man. J Steroid Biochem 1981;15:153-161.
19. Hofbauer LC, Gori F, Riggs LB, Lacey DL, Dunstan RD, Spelsberg TC, Khosla S: Stimulation of osteoprotegerin-ligand inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanism of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-4389.
20. Marcus R: Secondary form of osteoporosis; in Coe FL, Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York, Raven Press, 1992, pp 889-904.
21. Jee WSS, Park HZ, Roberts WE, Kenner GH: Corticosteroid and bone. Am J Anat 1970;129: 477-480.
22. Fuick RF, Kukreja SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA: Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 1975;40:152-185.
23. Gennari C, Bernini M, Nardi P, Fusi L, Francini G, Nami R, Montagnani M: Glucocorticoids: Radiocalcium and radiophosphate absorption in man; in Dixon A StJ, Russell RGG, Stamp TCB (eds): Osteoporosis, a Multidisciplinary Problem. London, Royal Society of Medicine, 1983, pp 75-80.
24. 3 on parathyroid hormone secretion in cultured bovine cells. Endocrinology 1989;125:638-641.
25. Au WY: Cortisol stimulation of parathyroid hormone secretion by rat parathyroid glands in organ culture. Science 1976;193:1015-1017.
26. Peraldi MN, Rondeau E, Jousset V, el M'selm A, Lacave R, Delarue F, Gerel JM, Sraer JD: Dexamethasone increases preproparathyroid hormone messenger RNA in hormone hyperplastic parathyroid cells in vitro. Eur J Clin Invest 1990;20:392-397.
27. Lukert BP, Adams JS: Calcium and phosphorous homeostasis in man. Effect of corticosteroids. Arch Intern Med 1976;136:1249-1253.
28. Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edourd C, Darby AJ: Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1979;1:303-319.
29. Hahn TS, Halstead LR, Teibelbaum SL, Hahn BH: Altered mineral metabolism in glucocorticoidinduced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest 1979;64: 655-665.
30. Suzuki Y, Ichikawa Y, Saito E, Homma M: Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32:151-156.
31. Gennari C: Glucocorticoid-induced osteoporosis. Clin Endocrinol 1994;41:273-274.
32. Slovik DM, Neer RM, Ohman JL, Lowell FC, Clark MB, Segre GV, Potts JT Jr: Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients. Clin Endocrinol 1980;12:243-248.
33. Seeman E, Kumar R, Hunder GG, Scott M, Heath H 3rd, Riggs BL: Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and chronic glucocorticoid excess. J Clin Invest 1980;66:664-669.
34. Hahn TJ, Halstead LR, Bran DT: Effects of short-term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentration in man. J Clin Endocrinol Metab 1981;52:111-115.
35. Nielsen HK, Thomsen K, Eriksen EF, Charles P, Storm T, Mosekilde L: The effects of high-dose glucocorticoid administration on serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner 1988;4:105-113.
36. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Samerwein HP: The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991; 72:382-386.
37. Gray RE, Doherty SM, Galloway J, Coulton L, de Broe M, Kanis JA: A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1991; 34:287-295.
38. Bikle DD, Halloran B, Fong L, Steinbach L, Shellito J: Elevated 1,25-dihydroxyvitamin D levels in patients with chronic obstructive pulmonary disease treated with prednisone. J Clin Endocrinol Metab 1993;76:456-461.
39. Hattersley AT, Meeran K, Burrin J, Hill P, Shiner R, Ibberston HK: The effect of long- and shortterm corticosteroids on plasma calcitonin and parathyroid hormone levels. Calcif Tissue Int 1994; 54:198-202.
40. Paz-Pacheo E, Fuleihan GEH, Leboff MS: Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J Bone Miner Res 1995;10:1713-1718.
41. Pearce G, Tabensky DA, Delmas PD, Baker HWG, Seeman E: Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998;83:801-806.
42. Gennari C, Bernini M, Nardi P, Fusi L, Nami R, Montagnani M: Hormones and the intestinal absorption of calcium and phosphate in man. Horm Res 1984;20:13-21.
43. Gennari C, Civitelli R: Glucocorticoid-induced osteoporosis. Clin Rheum Dis 1986;12:637-654.
44. Luengo M, Picado C, Piera C, Guanalabens N, Montserrat JM, Rivera J, Setoain J: Intestinal calcium absorption and parathyroid hormone secretion in asthmatic patients on prolonged oral or inhaled steroid treatment. Eur Respir J 1991;4:441-444.
45. Reid IR, Ibberston HK: Evidence for decreased tubular reabsorption of calcium in glucocorticoidtreated asthmatics. Horm Res 1987;27:200-204.
46. Wong GL: Basal activities and hormone responsiveness of osteoblastic activity. J Biol Chem 1979; 254:6337-6340.
47. Gennari C: Glucocorticoids and bone; in Peck WA (ed): Bone and Mineral Research. Amsterdam, Elsevier, 1985, pp 213-232.
48. Villareal DT, Civitelli R, Gennari C, Avioli LV: Is there an effective treatment for glucocorticoidinduced osteoporosis? Calcif Tissue Int 1991;49:141-142.
49. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ: A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update. J Intern Med 1998;244:271-292.
50. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, Suarez-Almazor ME: A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999; 26:1148-1157.
51. Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M, Gennari C: Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997; 61:382-385.
52. 3 receptors: Divergent effects on mouse and rat intestine. Endocrinology 1982;111:1400-1402.
53. 2 calcium, phosphate and sodium fluoride administration. Clin Endocrinol 1982;16:409-415.
54. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster DW, Cosman F: Randomized controlled study of the effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350:550-556.
55. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM: Prevention of estrogen deficiency-related bone loss with human parathyroid hormone (1-34): A randomized controlled trial. JAMA 1998;280:1067-1073.
56. Hodsman AB: Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation of quiescent cancellous surface. Bone 1993; 14:523-527.
57. Lane NE, Sanchez S, Gunnar WM, Genant HK, Pierini E, Arnaud CD: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998;102:1627-1633.
58. Bellido T, Plotkin L, Han L, Manolagas SC, Jilka RL: PTH prevents glucocorticoid-induced apoptosis of osteoblasts and osteoclasts in vitro: Direct interference with a private death pathway upstream from caspase-3 (abstract). Bone 1998;23:S518.